Figure 1.

Kaplan–Meier curves of the risk of natalizumab‐associated PML in the U.S. versus Europe, for JCV‐seropositive patients without prior IS exposure. Derived from Figure 2A in Ho et al.’s publication, ⁴ by branching the blue curve into two limbs via the regional JCV seroprevalence and the proportion of prior IS exposure in their cohort; ⁸ the continental distribution of PML cases was then approximated using information provided in Table 1 of the same source (Data S1). IS, immunosuppressant; JCV, John Cunningham virus; PML, progressive multifocal leukoencephalopathy.